The contract is a memorandum of understanding for the manufacturing by MaSTherCell of clinical batches of TxCell’s Ovasave.
TxCell, a biotechnology company, announced that it has entered into an agreement for the production of clinical batches of Ovasave with Belgium-based CMO MaSTherCell. Ovasave, TxCell’s lead product candidate, is a personalized T cell immunotherapy product based on the properties of autologous ovalbumin-specific regulatory T lymphocytes. A Phase IIb placebo controlled study (CATS29) has been initiated for refractory Crohn's disease. EMA has classed Ovasave as an advanced therapy medicinal product (ATMP).
The contract is a memorandum of understanding for the manufacturing by MaSTherCell of clinical batches of TxCell’s Ovasave. These Ovasave batches will be used by TxCell in Phase II evaluation of the product in refractory Crohn’s disease patients (CATS29 study). The transfer of technology will start immediately. The first clinical batches are expected to be manufactured in the second quarter of 2016.
TxCell is also taking measures to ensure full GMP compliance at its existing pilot Besançon manufacturing unit so that full manufacturing activities can begin following a partial temporary hold at the site. TxCell will file to re-obtain its GMP certificate and production will resume after approval of the GMP certificate by the French regulator ANSM.
Ovasave clinical batches for the CATS29 study will be manufactured in parallel by MaSTherCell and TxCell’s own facility. TxCell expects to announce top-line data from this study in 2017.
As part of the memorandum of understanding, TxCell and MaSTherCell will also discuss about the long-term clinical and commercial manufacturing by MaSTherCell of Ovasave and other TxCell products. The discussions are expected to take place in late 2015.
Source: TxCell
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.